Taken together, we demonstrated the cell interactions across immune cells and non-immune cells in colorectal tumors based on tumor sideness and mutation status, providing evidence for the combination therapy targeting immune checkpoints, growth factors and cytokine signaling, and providing additional support for the individualized treatment of colorectal cancer based on KRAS/TP53 mutation status. This evidence concerns the gene KRAS and colorectal neoplasm.